Zuranolone is a huge triumph for PPD—but it could negatively impact women's health research

The first-ever FDA-approved pill for postpartum depression is a landmark achievement, but it could come at a high cost for women in more ways than one.

Related Keywords

,Sage Therapeutics ,Sage Therapeutic ,Womens Health ,Clinical Depression ,Clinical Research ,Postpartum Depression ,Fda ,Zuranolone ,Hormone Imbalance ,Llopregnanolone ,Ewly Approved Drug ,Clinical Testing ,